Greenwich LifeSciences, Inc. filed a Definitive Proxy Statement (DEF 14A) on October 26, 2026, notifying stockholders of an annual meeting to be held on December 18, 2026, at which five board seats, auditor ratification, and executive compensation matters will be put to a vote.

Key Highlights

  • Annual meeting date: December 18, 2026, at 9:00 a.m. local time at Sheppard Mullin Richter & Hampton LLP, 30 Rockefeller Plaza, New York, NY.
  • Record date: October 26, 2026, with 14,678,208 shares of common stock outstanding as of that date.
  • Board election: Stockholders will vote on electing five members to the Board of Directors.
  • Auditor ratification: The appointment of MaloneBailey LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 is on the agenda.
  • Executive pay vote: An advisory vote on named executive officer compensation and a separate advisory vote on the frequency of future such votes are also proposed.
  • Notice mailing: A Notice of Internet Availability of Proxy Materials is expected to be mailed on or about October 28, 2026 to beneficial owners and stockholders of record.
  • Signed by: David B. McWilliams, Chairman of the Board of Directors, dated October 26, 2026.

Greenwich LifeSciences 2026 Annual Meeting: Five Proposals Before Stockholders

According to the filing, Greenwich LifeSciences, Inc. (NASDAQ:GLSI) issued its Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders, scheduled for December 18, 2026. The company disclosed that its Board of Directors fixed October 26, 2026 as the record date, and that as of that date, 14,678,208 shares of common stock were outstanding, with each share carrying one vote on each proposal.

The proxy statement sets out five agenda items for the annual meeting. First, stockholders will consider the election of five directors to the Board. Second, they will vote on ratifying the appointment of MaloneBailey LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Third and fourth, stockholders will cast advisory votes on the compensation of the company's named executive officers and on the preferred frequency of future such advisory votes. The fifth item covers any other business properly brought before the meeting.

The annual meeting will be held in person at Sheppard Mullin Richter & Hampton LLP, 30 Rockefeller Plaza, New York, NY. The filing notes that admission may require valid picture identification and proof of stock ownership as of the record date, and that cameras, recording devices, and other electronic devices will not be permitted. Proxy materials are available online at the address cited in the filing, and stockholders may vote by mail, in person, or via the Internet, according to the proxy statement. The notice of internet availability is expected to be distributed on or about October 28, 2026.

What Was Disclosed

Greenwich LifeSciences filed its 2026 Definitive Proxy Statement, detailing an annual stockholder meeting on December 18, 2026, with 14,678,208 shares eligible to vote as of the October 26, 2026 record date, and five proposals on the agenda including board elections and auditor ratification.